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Coccidioidomycosis is a systemic infection caused by the soil fungus Coccidioides immitis, which is endemic to the
south-western United States. Manifestations range from flu-like illness to pneumonia and septic shock. Diagnosis
may be delayed or missed in non-endemic areas because of the low index of suspicion.
We describe a series of 23 patients with coccidioidomycosis at one institution in a non-endemic area.
Diagnosis was often delayed. In two patients, the route of exposure could not be determined, but 20 patients had
a history of residence or travel to endemic areas, and the remaining patient had an occupational history of exposure
to fomites from an endemic region. Five patients were immunosuppressed. Most patients responded well to medical
therapy, surgery, or both.
Although coccidioidomycosis is rare in non-endemic areas, physicians must keep it in mind when evaluating
patients who have traveled to endemic areas or who are immunosuppressed.
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Coccidioidomycosis is a systemic infection caused by the
dimorphic fungus Coccidioides immitis. Initially recognized
by Posada in 1892 (1), C. immitis is a soil fungus that grows
in semi-arid areas and is endemic to the south-western
United States, areas of northern Mexico, and Central and
South America (2). Humans are infected by inhaling dust
containing the fungus spores, or arthroconidia (2,3). Under
usual circumstances, person-to-person transmission does
not occur. Risk factors for coccidioidomycosis include
extremes of age, living in or travel to an endemic area,
immunosuppressed state [including the acquired immuno-
deficiency syndrome (AIDS)] and pregnancy. African–
Americans, Filipinos and Hispanics are at an increased
risk of disseminated disease (4). Occupations that involve
handling laboratory specimens from infected individuals
are also associated with a higher risk (4). Prevalence of
infection in endemic areas, based on delayed dermalReceived 16 June 2000 and accepted in revised form 4 December
2000.
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dal antigens, estimates that about one-third of the
population is infected (5,6). Approximately 100 000 infec-
tions occur in the U.S.A. each year (7). Based on a study of
students utilizing the health service at the University of
Arizona, the average annual incidence has been estimated
at 0?43% (8).
Coccidioidomycosis is asymptomatic in most patients
(60%), but may have manifestations ranging from flu-like
illness (approximately 15%) to pneumonia and septic shock
(2,9). The disease may occur as (i) primary pulmonary
coccidioidomycosis, (ii) chronic progressive pulmonary
coccidioidomycosis, or (iii) disseminated coccidioidomyco-
sis. The disease may recur years after exposure or apparent
cure and recurrent disease can manifest itself as any of the
three types. Other manifestations include skin lesions such
as erythema nodosum and marginatum, and arthritis.
Although coccidioidomycosis may be readily suspected
in patients living in endemic areas, the diagnosis may be
delayed or missed in non-endemic areas because of a low
index of suspicion (10,11). To learn more about how cases
were diagnosed and treated in a non-endemic area, we
reviewed records from our institution and identified 23
cases of confirmed coccidioidomycosis. In this article, we
review these cases, focusing primarily on presenting
features, diagnosis and therapies. We present more detailed# 2001 HARCOURT PUBLISHERS LTD
TABLE 1. Characteristics and risk factors in 23 patients with
coccidioidomycosis
Characteristic Number of patients
(n=23)
Mean age (range) 51?9 years (22–72)
Age 465 5 (22%)
Number of men 11 (48%)
Race
Caucasian 22 (96%)
Black 1 (4%)
History of exposure
Travel to endemic area 11 (48%)
Residence in endemic area 9 (39%)
Exposure to fomites 1 (4%)
No known exposure 2 (9%)
Smokers 14 (61%)
Active 3 (13%)
Former 11 (48%)
Co-morbid conditions* 16 (70%)
Diabetes mellitus 6 (26%)
History of malignancy 2 (9%)
Systemic steroids 4 (17%)
COPD{ 2 (9%)
Asthma 3 (13%)
*Patients can have more than one co-morbid conditon.
{COPD: chronic obstructive pulmonary disease.
TABLE 2. Testing methods and numbers of positive results in
23 patients with coccidioidomycosis
Testing method* Number of positive results
Cultures (n 12 patients)
Bronchoalveolar lavage 5
Sputum 5
Lung biopsy 2
Lymph node 1
Knee (synovium) 1
Pathology (n 12 patients)
Lung 9
Skin 1
Lymph node 1
Knee (synovium) 1
Autopsy 1
Serology (n 17 patients)
Complement fixation 17
Immunodiffusion 10
*Patients can have more than one positive test.
306 S. A. DESAI ET AL.descriptions of two patients with unusual histories and
presentations.
Materials and methods
The Cleveland Clinic Foundation is a 950-bed tertiary
referral center in north-eastern Ohio. The majority of the
population served by the institution lives in Ohio and
surrounding states, which are not considered to be endemic
for C. immitis. Cases were identified by retrospective review
of pathology reports between 1980 and 1998, and of
microbiology and fungal serology reports between 1975 and
1998. Cases were defined by a culture positive for C.
immitis, histopathological findings consistent with the
disease, positive serologic tests or any combination of these
three findings.
Medical records of identified patients were reviewed
retrospectively for host factors, demographics, risk factors,
history or date of potential exposure, clinical presentation,
co-morbid conditions [such as diabetes mellitus, coronary
artery disease, hypertension, chronic renal failure, asthma,
chronic obstructive pulmonary disease (COPD), immuno-
suppression], delay between presentation and diagnosis,
and therapeutic interventions.
Results
Twenty-nine patients with coccidioidomycosis infection
were identified. Charts of 23 of them were available for
review. Table 1 describes characteristics and the potential
risk factors in our patient population. Sixteen patients had
at least one co-morbid condition. Of the patients with a
history of malignancy, one patient had a past history of
primary colon cancer and primary bladder cancer, and the
other had a basal cell carcinoma excised approximately 1
year prior to being diagnosed with coccidioidomycosis.
Serologic, culture, and histopathology results are listed in
Table 2. Symptoms developed a median of 17 months after
presumed exposure (range: 2 weeks–11?75 years). The
diagnosis was made a median of 3 months after symptom
onset (range: 4 weeks–14 months).
PRESENTATION
Most patients (20 of 23) presented with respiratory
symptoms including cough (n 12), dyspnea (n 6), and
hemoptysis (n 4). Inspiratory crackles (n 6), expiratory
wheezes (n 3), and ronchi (n 3) were the findings on lung
examination. Two patients were asymptomatic with abnor-
mal chest radiographs, and the remaining patient presented
with knee swelling. The clinical presentation was consistent
with primary pulmonary coccidioidomycosis in 11 patients,
and seven patients presented with chronic pulmonary
disease (Table 3). Other constitutional symptoms included
fever (n 9), weight loss (n 6), fatigue (n 6), night
sweats (n 4), and rash (n 3). Chest radiographs were
abnormal in 22 patients (Table 4).TREATMENT
One patient did not receive treatment and died
of respiratory failure. A diagnosis of disseminated
TABLE 3. Clinical presentation of coccidioidomycosis in 23
patients
Form n
Primary pulmonary coccidioidomycosis 18
Acute 11
Chronic 7
Disseminated coccidioidomycosis 2
Reactivation coccidioidomycosis 1
Asymptomatic 2
TABLE 4. Radiographical manifestations of coccidioidomy-
cosis in 23 patients
Manifestation* n (%)
Solitary nodule 9 (39)
Patchy infiltrate 7 (30)
Cavitary lesion 6 (26)
Miliary infiltrate 1 (4)
Bronchopleural fistula 1 (4)
None 1 (4)
*Patients could have more than one manifestation.
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were followed with observation only: one had spontaneous
remission, and the other developed chronic recurrent
disease. The other 20 patients received medical therapy,
surgical therapy or both. Medical therapy consisted of
either itraconazole or ketoconazole alone, intravenous
amphotericin B alone, amphotericin B with itraconazole
or ketoconazole, or in one case, amphotericin B with
transfer factor. Surgical therapy consisted of lobectomy
and wedge resection of lung tissue, and in one case,
synovectomy of the knee joint. Combined surgical and
medical therapy consisted of lung resection with itracona-
zole and knee synovectomy with amphotericin B.
CASE PRESENTATIONS
We describe two patients, one who had an unusual route of
exposure and the other who had unusual clinical manifesta-
tions.
Patient 1
The patient, a 59-year-old black man who smoked and had
sickle cell trait, had no history of travel outside Ohio.
However, he worked as a maintenance man in a storage
facility that received material (such as graphite) from
Mexico. He presented to our institution with high fever, dry
cough, weight loss and night sweats of 3 months duration.A chest radiograph showed bilateral miliary infiltrates with
a right upper lobe mass. Sputum and subcarinal lymph
node biopsy cultures and serologic tests were positive for C.
immitis. A skin test for tuberculosis was negative. After
treatment with amphotericin B and transfer factor for 2
months, his symptoms and right upper lobe mass resolved.
The chest radiograph showed persistent but improved
infiltrates.
Patient 2
The patient was a 72-year-old white man who spent his
winters in Arizona and was admitted at our institution with
hypothermia, dehydration, a generalized, pruritic, maculo-
papular rash (Fig. 1), peripheral eosinophilia and a clear
chest radiograph. A skin biopsy was consistent with
cutaneous T-cell lymphoma, and he was treated for this
without improvement. He later developed fever, cough and
a new left lower lobe infiltrate. The patient was given
broad-spectrum antibiotics. His condition worsened and he
required transfer to the medical intensive care unit, with
mechanical ventilatory support and systemic steroid ther-
apy for a suspected vasculitic process. After initial
improvement, he deteriorated rapidly and died. On the
day prior to his death, the bronchoalveolar specimen
revealed C. immitis. An autopsy revealed disseminated
coccidioidomycosis involving skin, lungs (panlobar with
multiple abscesses; Fig. 2), kidneys, spleen and lymph
nodes.
Discussion
We describe the largest case series of coccidioidomycosis
reported from a non-endemic area in the U.S.A. Tradi-
tionally, coccidioidomycosis has been limited to the south-
western United States. In the current era of increasing
travel, increased immunosuppressant use, and the AIDS
epidemic, coccidioidomycosis should be kept in mind even
in non-endemic areas.
We found a relatively long time interval from onset of
symptoms to diagnosis, which we attribute, in part, to the
low index of suspicion among physicians in our area. In
addition, although the majority of patients in our study (20
of 23) had a history of exposure to coccidioidomycosis, some
had no known history of exposure or were exposed only by
contact with fomites. Patient 1 may be the first patient living
in a non-endemic area infected with coccidioidomycosis
through contact with fomites from an endemic area. Patient
2 highlights a rare presentation of coccidioidomycosis. The
diffuse rash described with coccidioidomycosis is a hyper-
sensitivity reaction and not direct cutaneous involvement
with C. immitis (4,7,8). Direct cutaneous involvement with
C. immitis, as a result of disseminated disease, is usually
localized, presenting as papules, pustules, nodules, sinuses or
ulcers (8). To our knowledge, this patient is only the second
to be described with direct diffuse cutaneous involvement
presenting as a rash masquerading as mycosis fungoides
(Sezary syndrome) (1).
FIG. 1. A 72-year-old gentleman with a generalized, pruritic, maculopapular rash.
FIG. 2. Fungal stain of lung tissue showing panlobar coccidioidomycosis with multiple abscesses.
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symptoms was variable, ranging from less than 1 month to
12 years. Fourteen of the 23 patients had a history of
tobacco smoking. Smoking has not previously been
identified as a significant risk factor (4,8) and whether this
high prevalence of smoking among our patients is a
coincidental finding or a true risk factor awaits further
study. Although age and ethnicity were not identified as
dominant risk factors, we attribute this to regional
demographical differences.Coccidioidomycosis is never a commensal, so a positive
culture from the respiratory tract is diagnostic. Because the
primary site of inoculation and infection is the respiratory
tract, positive specimens are often obtained from the lungs.
In our patients, 12 of the 14 positive cultures and 10 of the
13 positive histology specimens were obtained from the
lungs (including the autopsy study). As opposed to other
fungal diseases, serologic testing is extremely useful in
immunocompetent patients with coccidioidomycosis since
the CF test has diagnostic as well as prognostic
COCCIDIOIDOMYCOSIS IN NON-ENDEMIC AREAS: A CASE SERIES 309implications. A positive test is indicative of previous
infection and a titer 1:16 is associated with an increased
likelihood of dissemination. In our series, at least one
serological test was positive in all 17 patients who under-
went serological testing.
Although not considered the primary therapy for
primary pulmonary disease, in this series surgery was
performed in patients with primary pulmonary disease
predominantly to rule out a malignant process. Patients
with localized extra-pulmonary disease also underwent
surgery in some cases, with good results. It is unclear
whether the patient with coccidioidomycosis 20 years after
resection of a solitary nodule had recurrent disease or a
second infection. Medical therapy cured or improved the
status of most patients so treated. Treatment modalities
were chosen based on the severity and location of disease,
as well as the patient’s co-morbid conditions.
We agree with a recent review (12) that persons at risk for
infection should be educated about common manifestations
of coccidioidomycosis. We also think that physicians
working in non-endemic areas should be aware of the
clinical presentations of the disease in order to facilitate
diagnosis.
Conclusions
The clinical manifestations of coccidioidomycosis are
variable and non-specific, but may include respiratory
symptoms, nodules or other abnormalities on chest radio-
graphs and constitutional symptoms. Determining a history
of exposure is critical in making the diagnosis of
coccidioidomycosis, especially in a non-endemic area, since
primary disease or reactivation can occur years after the
last known exposure or primary disease. In patients who
have no evidence of exposure to C. immitis by travel
history, the occupational history may be helpful. Although
disseminated infection is rare, the consequences can be
devastating. Patients respond well to therapy if diagnosed
and treated promptly. Coccidioidomycosis may be readily
diagnosed in an endemic area because of the high index of
suspicion, but physicians in non-endemic areas should alsoconsider the diagnosis in patients with a history of exposure
and/or predisposing conditions.
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